Loading...
•
Sep 30, 2024
Grail Inc Q3 2024 Earnings Report
GRAIL's third quarter of 2024 financial results were reported, featuring a 52% year-over-year growth in Galleri revenue, which reached $25.4 million, and commercial Galleri sales surpassing 250,000 tests since launch, with a cash balance of $853.6 million providing runway into 2028.
Key Takeaways
GRAIL reported a 38% increase in total revenue to $28.7 million, with Galleri revenue growing by 52% to $25.4 million. The company's net loss was $125.7 million, while adjusted EBITDA showed an improvement. Over 250,000 Galleri tests have been sold since launch, and the company is focusing on cost management and advancing registrational studies.
Total revenue increased by 38% year-over-year to $28.7 million.
Galleri revenue grew by 52% year-over-year to $25.4 million.
Net loss was $125.7 million, including amortization and restructuring charges.
Cash and cash equivalents totaled $853.6 million as of September 30, 2024.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The press release contains forward-looking statements regarding GRAIL's future financial performance, products, clinical studies, regulatory compliance, market opportunity, growth strategies, and cash sufficiency. These statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...